Therapeutic Solutions International, Inc. Announces the Appointment of Dr. Barry Glassman as Vice President of Training and Education

OCEANSIDE, CA--(Marketwire - Feb 11, 2013) - Therapeutic Solutions International, Inc. (OTCQB: TSOI) announced today the appointment of Barry Glassman, D.M.D., as Vice President of Training and Education.

Dr. Glassman maintains a private practice which is limited to chronic pain management, temporomandibular joint dysfunction and dental sleep medicine. He is a Diplomate of the American Academy of Craniofacial Pain and the American Academy of Pain Management, as well as a Fellow of the International College of Craniomandibular Orthopedics and the Academy of Dentistry International, and he is on the staff at the Lehigh Valley Hospital (Allentown, Pennsylvania) where he serves as a resident instructor of Craniofacial Pain and Dysfunction and Dental Sleep Medicine.

"This appointment of Dr. Glassman as Vice President of Training and Education for Therapeutic Solutions International will allow us to provide quality training for AMPSA products worldwide," stated Tim Dixon, CEO of Therapeutic Solutions International, who added, "Dr. Glassman is a popular and dynamic speaker on both the National and International lecture circuits and will bring world class education and training to AMPSA customers."

Dr. Glassman said, "Anterior Midpoint Stop Appliances (AMPSA) have become the keystone to our chronic pain practice. We have learned how these appliances can benefit general dentists and with minimal training and how incredibly helpful they are for patients."

Dr. Glassman added, "AMPSA therapy can be extremely effective for many Orofacial pain conditions including headache and migraine. I look forward to the opportunity to educate dentists worldwide as they learn the expanding role they can play in their patients' health. Therapeutic Solutions International is a forward looking company with which I am proud to be associated. I look forward to its growth as it plays a major role in health care worldwide."

As previously announced, Therapeutic Solutions International has been approved as a PACE Provider of Dental Continuing Education by the Academy of General Dentistry. The Program Approval for Continuing Education (PACE) of the Academy of General Dentistry (AGD) is for Members of the AGD that seek PACE-approved CE providers to help them earn the quality CE they need to maintain their membership and achieve AGD's prestigious Fellowship (FAGD) and Mastership (MAGD) awards. 

Dr. Glassman has been a speaker at the Academy of Pain Management, the International College of Craniomandibular Disorders, the Academy of Orofacial Pain, the Academy of Craniofacial Pain, the International Academy of Gnathology, the American Equilibrium Society, and the American Academy of Dental Sleep Medicine. His topics include headache, chronic pain, joint dysfunction, and sleep disorders.

Dr. Glassman has had a number of articles on pain management and sleep disorders published in both peer and non-peer reviewed journals. His editorials and articles on joint dysfunction, appliance therapy, and sleep disorders have appeared in Cranio, Inside Dentistry, Pain Management, and others.

Dr. Glassman is the recipient of the prestigious Haden-Stack award, given by the American Academy of Craniofacial Pain for his dedication to education. His courses are well known for their evidence based concepts taught in an evidence based educational method that encourages understanding versus memorization. This greatly increases the likelihood of the attendee moving forward with implementation of the material.

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is a global manufacturer of the chairside anterior midpoint stop appliance (AMPSA) devices marketed internationally under the trade names Migran-X® and AMPSA CS®, which have helped countless patients prevent debilitating migraine and tension headache pain, bruxism, clenching, grinding, and TMJ disorders. The Migran-X® and AMPSA CS® devices are the most effective non-drug US FDA cleared dental method of migraine prevention on the market today. Dentists fit the AMPSA devices on patients for the treatment of medically diagnosed migraine pain, as well as migraine associated tension-type headaches, in order to reduce their migraine signs and symptoms through the reduction of trigeminally innervated muscular activity, and to prevent bruxism and TMJ syndrome through the reduction of trigeminally innervated muscular activity. In clinical trials reviewed by the US FDA, 82% of medically diagnosed migraine sufferers using the Migran-X device averaged a 77% average reduction of migraine events in the first eight weeks of use. Successful outcomes are produced by reducing head, neck and jaw muscle contraction intensity by nearly 70%. Therapeutic Solutions International also licenses laboratories to manufacture and sell semi-custom AMPSA devices internationally. The Company is also a provider of continuing education programs in the United States focused on AMPSA devices. The Company does not sell AMPSA products in the United States. The Company's corporate website is www.therapeuticsolutionsint.com. Non-US dentists and physicians can order our AMPSA products at www.ordertsoi.com.

Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to the need for further financing, our exit from the US market for AMPSA products in 2013, the need to procure additional international distributors, direct competition beginning in 2013, reliance on key personnel, possible introduction of new product lines, and other specific risks set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Readers are advised to review our filings with the Securities and Exchange Commission that can be accessed over the Internet at the SEC's website located at www.sec.gov.